Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C

British Journal of Dermatology

Volumn 168, Issue 3, 2013, Pages 461-462

  Warren, R B ^a   Fai, A Al Ri ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; NOTE; PSORIASIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875474727     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12227     Document Type: Editorial

References (13)

1. Navarro R, Vilarrasa E, Herranz P et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013;168:609-16.
2. Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in an HBsAg negative anti-HBs positive patient. Br J Dermatol 2013;168:679-80.
3. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74-81.
4. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-62.
5. Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat 2012;19:1-8.
6. Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;5:167-9.
7. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of antitumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology 2011;50:1700-11.
8. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
9. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(Suppl.1): S35-50.
10. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
11. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2012; Oct. 30 [Epub ahead of print]
12. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
13. Burden AD, Warren RB, Kleyn CE et al. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol 2012;166:545-54.